| Medical and Health Sciences | Lifetime | 249 | IT 11 | 99.99 |
| Hematology | Lifetime | 15 | IT 1 | 99.92 |
| Medical Genetics | Lifetime | 77 | IT 7 | 99.43 |
| Internal Medicine | Lifetime | 35 | IT 4 | 99.29 |
| Cardiology and Cardiovascular Medicine | Lifetime | 807 | IT 37 | 98.28 |
| Immunology | Lifetime | 893 | IT 29 | 96.99 |
| Hepatology | Lifetime | 338 | IT 25 | 97.18 |
| Geriatrics and Gerontology | Lifetime | 231 | IT 7 | 94.39 |
| Medical Biochemistry | Lifetime | 633 | IT 32 | 75.40 |
| Hematology | 2021-2025 | 102 | IT 6 | 97.80 |
| Speech and Hearing | 2021-2025 | 128 | IT 2 | 88.37 |
| Health, Toxicology and Mutagenesis | 2021-2025 | 707 | IT 12 | 83.44 |
| Platelet Disorders and Treatments | Lifetime | 2 | IT 1 | 99.92 |
| Blood Coagulation and Thrombosis Mechanisms | Lifetime | 2 | IT 1 | 99.90 |
| Hemophilia Treatment and Research | Lifetime | 1 | IT 1 | 99.96 |
| Blood groups and transfusion | Lifetime | 4 | IT 1 | 99.76 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 4 | IT 1 | 99.81 |
| Hemostasis and retained surgical items | Lifetime | 1 | IT 1 | 99.90 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 20 | IT 1 | 99.87 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 3 | IT 1 | 99.76 |
| Complement system in diseases | Lifetime | 24 | IT 2 | 99.39 |
| Cancer-related gene regulation | Lifetime | 75 | IT 1 | 99.39 |
| Blood properties and coagulation | Lifetime | 45 | IT 4 | 99.17 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 63 | IT 9 | 99.39 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 190 | IT 10 | 99.44 |
| Blood disorders and treatments | Lifetime | 88 | IT 1 | 98.50 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 198 | IT 15 | 98.96 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 286 | IT 25 | 98.59 |
| Liver Disease and Transplantation | Lifetime | 530 | IT 47 | 98.62 |
| Pharmaceutical Practices and Patient Outcomes | Lifetime | 280 | IT 8 | 97.58 |
| Parvovirus B19 Infection Studies | Lifetime | 157 | IT 11 | 97.98 |
| Climate Change and Health Impacts | Lifetime | 323 | IT 7 | 97.64 |
| Hepatitis C virus research | Lifetime | 682 | IT 57 | 98.22 |
| Vitamin K Research Studies | Lifetime | 74 | IT 3 | 96.98 |
| Hepatitis B Virus Studies | Lifetime | 776 | IT 44 | 98.08 |
| Renal Diseases and Glomerulopathies | Lifetime | 528 | IT 40 | 97.57 |
| Trauma, Hemostasis, Coagulopathy, Resuscitation | Lifetime | 217 | IT 9 | 97.47 |
| Blood transfusion and management | Lifetime | 228 | IT 5 | 96.50 |
| Chronic Disease Management Strategies | Lifetime | 632 | IT 13 | 96.45 |
| Blood donation and transfusion practices | Lifetime | 161 | IT 3 | 96.27 |
| Erythropoietin and Anemia Treatment | Lifetime | 523 | IT 29 | 92.92 |
| COVID-19 impact on air quality | Lifetime | 484 | IT 24 | 77.96 |
| Clinical Laboratory Practices and Quality Control | Lifetime | 844 | IT 52 | 80.34 |
| Hemophilia Treatment and Research | 2021-2025 | 29 | IT 4 | 98.23 |
| Platelet Disorders and Treatments | 2021-2025 | 122 | IT 13 | 95.85 |
| Blood Coagulation and Thrombosis Mechanisms | 2021-2025 | 161 | IT 14 | 90.12 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 149 | IT 11 | 85.19 |
| Healthcare cost, quality, practices | 2021-2025 | 674 | IT 11 | 74.75 |
| Blood groups and transfusion | 2021-2025 | 796 | IT 62 | 75.64 |
| Blood disorders and treatments | 2021-2025 | 489 | IT 57 | 71.54 |
| Blood properties and coagulation | 2021-2025 | 494 | IT 29 | 67.78 |
| Hemostasis and retained surgical items | 2021-2025 | 423 | IT 8 | 52.12 |
